Bayforest Capital Ltd Sells 10,574 Shares of Lantheus Holdings, Inc. $LNTH

Bayforest Capital Ltd trimmed its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 94.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 578 shares of the medical equipment provider’s stock after selling 10,574 shares during the period. Bayforest Capital Ltd’s holdings in Lantheus were worth $38,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of LNTH. Hantz Financial Services Inc. grew its stake in Lantheus by 412.5% in the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 396 shares in the last quarter. First Horizon Corp purchased a new position in Lantheus in the 3rd quarter valued at approximately $26,000. Osterweis Capital Management Inc. purchased a new position in Lantheus in the 2nd quarter valued at approximately $36,000. Farther Finance Advisors LLC grew its stake in Lantheus by 71.4% in the 4th quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 275 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd purchased a new position in Lantheus in the 3rd quarter valued at approximately $55,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Trading Down 0.1%

LNTH opened at $82.82 on Friday. The business has a 50 day simple moving average of $77.62 and a two-hundred day simple moving average of $66.95. The firm has a market capitalization of $5.39 billion, a price-to-earnings ratio of 24.58 and a beta of -0.12. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.70 and a quick ratio of 2.51. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $108.91.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 EPS for the quarter, beating analysts’ consensus estimates of $1.17 by $0.50. Lantheus had a return on equity of 30.77% and a net margin of 15.15%.The business had revenue of $406.79 million during the quarter, compared to analyst estimates of $367.03 million. During the same quarter in the prior year, the company posted $1.59 EPS. Lantheus’s quarterly revenue was up 4.0% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Analysts predict that Lantheus Holdings, Inc. will post 4.29 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on LNTH shares. JonesTrading lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, February 27th. Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. Mizuho raised their price objective on shares of Lantheus from $85.00 to $95.00 and gave the company an “outperform” rating in a research report on Monday, April 13th. Citizens Jmp raised their price objective on shares of Lantheus from $73.00 to $78.00 and gave the company a “market outperform” rating in a research report on Tuesday, February 24th. Finally, Wall Street Zen upgraded shares of Lantheus from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 28th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Lantheus has an average rating of “Moderate Buy” and an average target price of $88.86.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.